Creative Medical Technology Announces Its ADAPT Trial To Study Its CELZ-201 Is 85% Enrolled
Dear Fellow Shareholder: Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis ("OA"), immunotherapy, and biodefense. This progress, combined with disciplined capital allocation and expand